Lexaria’s Human Clinical Nicotine Study Completes Dosing as Planned
KELOWNA, BC / ACCESSWIRE / May 8, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces that dosing of the targeted 36…
Lexaria Bioscience Continues To Execute
Last week, Lexaria Bioscience Corp. (Nasdaq: LEXX) reported two major developments that our readers should be aware of. The more significant announcement was Lexaria awarding a contract for clinical research…
LevelJump Healthcare Is On The Move…This Is Just The Beginning
A few weeks ago, we highlighted LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) as an emerging growth story that is flying under the radar. We hope you followed…
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
KELOWNA, BC / ACCESSWIRE / April 24, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has awarded the contract for…
Lexaria Biosciences: An Undervalued Biotech Opportunity
When analyzing biotech companies, positive clinical trial results are the most significant potential catalyst for businesses. For this reason, we are favorable on companies that have been reporting positive results…
LevelJump Healthcare: A Deep Dive
LevelJump Healthcare Corp. (TSXV: JUMP) (OTCQB: JMPHF) (FSE: 75J) is an emerging growth story and we believe the business is flying under the radar. The company provides telehealth solutions to…
Lexaria Bioscience: A Growth Story That Is Flying Under The Radar
Last week, Lexaria Bioscience Corp. (Nasdaq: LEXX) reported additional findings from its human clinical study HYPER-H21-4 which demonstrated a potentially novel mechanism of action of its patented DehydraTECH-processed cannabidiol (CBD)…
Lexaria Discovers Potential Novel Mechanism From Hypertension Study HYPER-H21-4
KELOWNA, BC / ACCESSWIRE / February 21, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce additional findings from its human…
Lexaria Bioscience: An Undervalued Growth Story
Earlier this year, we highlighted Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) as an undervalued biotech company and want to provide more information on the story. During the last year,…
CEO Spotlight: Lexaria Bioscience
Today, we are lucky to have Lexaria Bioscience CEO Chris Bunka with us. During the last year, the biotech company has reported a series of positive developments and we are…
